Yonsei Med J.  2010 Mar;51(2):261-269. 10.3349/ymj.2010.51.2.261.

Drug Attitude and Adherence to Anti-Glaucoma Medication

• Hong S
• Kang SY
• Yoon JU
• Kang U
• Seong GJ
• Kim CY

• KMID: 1126028
• DOI: http://doi.org/10.3349/ymj.2010.51.2.261

Abstract

PURPOSE
The purpose of this study is to assess patient attitudes towards anti-glaucoma medication and their association with adherence, visual quality of life, and personality traits.
MATERIALS AND METHODS
One hundred and forty-seven glaucoma patients were enrolled this study. The participants were divided into 'pharmacophobic' and 'pharmacophilic' groups according to their scores on the Modified Glaucoma Drug Attitude Inventory (MG-DAI). To establish a correlation with patient drug attitude, each group had their subjective drug adherence, visual quality of life, and personality traits examined. For personality traits, the Myers-Briggs Type Indicator (MBTI) was used to sub-classify each group.
RESULTS
Among the patients analyzed, 91 (72.80%) patients showed a 'pharmacophobic' attitude and 34 (27.20%) patients showed a 'pharmacophilic' attitude. The pharmacophobic group tended to have worse adherence than the pharmacophilic group. Personality dichotomies from the MBTI also showed different patterns for each group.
CONCLUSION
In glaucoma patients, pharmacological adherence was influenced by their attitude towards drugs; an association might exist between drug attitude and underlying personality traits.

Keyword

Adherence; drug attitude; glaucoma; personality

MeSH Terms

Adult
Aged
Attitude
Female
Glaucoma/*drug therapy
Humans
Male
Middle Aged
Patient Compliance/*psychology
Personality Inventory
Questionnaires

Figure

• 

  Fig. 1 Relationship between the Modified Glaucoma Drug Attitude Inventory (MG-DAI) scores and the subjective drug adherence scores.

Reference

1. World Health Organization (WHO). Conquering suffering, enriching humanity. The World Health Report 1997. 1997. Geneva: WHO;68–69.

2. World Health Organization (WHO). Changing history. The World health report 2004. 2004. Geneva: WHO;128–129.

3. Zimmerman TJ, Zalta AH. Facilitating patient compliance in glaucoma therapy. Surv Ophthalmol. 1983. 28:Suppl 1. 252–258.

4. Lee MD, Fechtner FR, Fiscella RG, Singh K, Stewart WC. Emerging perspectives on glaucoma: highlights of a roundtable discussion. Am J Ophthalmol. 2000. 130:S1–S11.

5. Ashburn FS Jr, Goldberg I, Kass MA. Compliance with ocular therapy. Surv Ophthalmol. 1980. 24:237–248.

6. Davidsön SI, Akingbehin T. Compliance in ophthalmology. Trans Ophthalmol Soc U K. 1980. 100:286–290.

7. Granström PA, Norell S. Visual ability and drug regimen: relation to compliance with glaucoma therapy. Acta Ophthalmol (Copenh). 1983. 61:206–219.

8. Spaeth GL. Visual loss in a glaucoma clinic. I. Sociological considerations. Invest Ophthalmol. 1970. 9:73–82.

9. Chang JS Jr, Lee DA, Petursson G, Spaeth G, Zimmerman TJ, Hoskins HD, et al. The effect of a glaucoma medication reminder cap on patient compliance and intraocular pressure. J Ocul Pharmacol. 1991. 7:117–124.

10. Riffenburgh Rs. Doctor-patient relationship in glaucoma therapy. Arch Ophthalmol. 1966. 75:204–206.

11. Bloch S, Rosenthal AR, Friedman L, Caldarolla P. Patient compliance in glaucoma. Br J Ophthalmol. 1977. 61:531–534.

12. Demailly P, Zoute C, Castro D. [Personalities and chronic glaucoma]. J Fr Ophtalmol. 1989. 12:595–601.

13. Wilson MR, Coleman AL, Yu F, Fong Sasaki I, Bing EG, Kim MH. Depression in patients with glaucoma as measured by self-report surveys. Ophthalmology. 2002. 109:1018–1022.

14. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med. 1983. 13:177–183.

15. Sibitz I, Katschnig H, Goessler R, Unger A, Amering M. Pharmacophilia and pharmacophobia: determinants of patients' attitudes towards antipsychotic medication. Pharmacopsychiatry. 2005. 38:107–112.

16. Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD. NEI-VFQ Field Test Investigators. Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). Arch Ophthalmol. 1998. 116:1496–1504.

17. Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD. National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001. 119:1050–1058.

18. Mangione CM. The National Eye Institute 25-Item Visual Function Questionnaire (VFQ-25). NEI VFQ-25 Scoring Algorithm-August 2000. Available at: http://www.nei.nih.gov/resources/visionfunction/manual_cm2000.pdf.

19. Sim HC. A cross-cultural study of a personality inventory: The development and validation of the Myers-Briggs Type Indicator in the Korean language. 1990. St. Louis: Saint Louis University.

20. Kim J, Sim H, Je S. Development and use of MBTI. 1995. Seoul: KPTI.

21. Guillausseau PJ. Impact of compliance with oral antihyperglycemic agents on health outcomes in type 2 diabetes mellitus: a focus on frequency of administration. Treat Endocrinol. 2005. 4:167–175.

22. Marquis RE, Whitson JT. Management of glaucoma: focus on pharmacological therapy. Drugs Aging. 2005. 22:1–21.

23. Vakil N. Increasing compliance with long-term therapy: avoiding complications and adverse events. Rev Gastroenterol Disord. 2005. 5:Suppl 2. S12–S17.

24. Cortet B, Bénichou O. Adherence, persistence, concordance: do we provide optimal management to our patients with osteoporosis? Joint Bone Spine. 2006. 73:e1–e7.

25. Costantini L. Compliance, adherence, and self-management: is a paradigm shift possible for chronic kidney disease clients? CANNT J. 2006. 16:22–26.

26. Gold DT, McClung B. Approaches to patient education: emphasizing the long-term value of compliance and persistence. Am J Med. 2006. 119:S32–S37.

27. López-Sanromán A, Bermejo F. Review article: how to control and improve adherence to therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2006. 24:Suppl 3. 45–49.

28. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000. 160:2101–2107.

29. Druss BG, Rosenheck RA, Desai MM, Perlin JB. Quality of preventive medical care for patients with mental disorders. Med Care. 2002. 40:129–136.

30. Katon WJ. Clinical and health services relationships between major depression, depressive symptoms, and general medical illness. Biol Psychiatry. 2003. 54:216–226.

31. Pappa C, Hyphantis T, Pappa S, Aspiotis M, Stefaniotou M, Kitsos G, et al. Psychiatric manifestations and personality traits associated with compliance with glaucoma treatment. J Psychosom Res. 2006. 61:609–617.

32. Fielder AR, Irwin M, Auld R, Cocker KD, Jones HS, Moseley MJ. Compliance in amblyopia therapy: objective monitoring of occlusion. Br J Ophthalmol. 1995. 79:585–589.

33. Oelzner S, Brandstädt A, Hoffmann A. Correlations between subjective compliance, objective compliance, and factors determining compliance in geriatric hypertensive patients treated with triamterene and hydrochlorothiazide. Int J Clin Pharmacol Ther. 1996. 34:236–242.

34. Kudielka BM, Broderick JE, Kirschbaum C. Compliance with saliva sampling protocols: electronic monitoring reveals invalid cortisol daytime profiles in noncompliant subjects. Psychosom Med. 2003. 65:313–319.

35. Bos A, Kleverlaan CJ, Hoogstraten J, Prahl-Andersen B, Kuitert R. Comparing subjective and objective measures of headgear compliance. Am J Orthod Dentofacial Orthop. 2007. 132:801–805.